drugset / Trial / NCT06550895
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
NaSequentialOpen-labelTreatment
Summary
The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple myeloma (MM).
Timeline
- Start
- 2024-09-16
- Primary completion
- 2027-08-26
- Completion
- 2027-08-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Talquetamab | Monoclonal antibody | — | Subcutaneous |
| Subject | ciltacabtagene autoleucel | Cell therapy | — | Intravenous |